Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies.

Ghosh, Anna K; Spriggs, A. I.; Taylor‐Papadimitriou, Joyce; Mason, David Y.

doi:10.1136/jcp.36.10.1154

Cited by 105 publications

(37 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In some cases differentiating between reactive mesothelial cells, mesothelioma, and adenocarcinoma can be problematic. Tumour markers such as carcinoembryonic antigen (CEA), Leu-1, and mucin, may be helpful in establishing the diagnosis, as they are frequently positive in adenocarcinomas (50-90%) but rarely seen with mesothelial cells or mesothelioma (0-10%) [61][62][63][64][65][66][67][68][69][70][71].…”

Section: Diagnostic Thoracentesismentioning

confidence: 99%

Management of malignant pleural effusions

et al. 2001

View full text Add to dashboard Cite

Section: Diagnostic Thoracentesismentioning

confidence: 99%

Management of malignant pleural effusions

et al. 2001

View full text Add to dashboard Cite

“…Although the cytopathological analysis either of metastatic effusions or of FNA of non-palpable lesions detected on CT-scan represents a useful diagnostic tool for the staging and monitoring of patients bearing a colon-rectum cancer, it requires considerable experience and a correct morphological diagnosis of tumour origin, which can be made only in the clinical context of a known primary tumour (Ghosh et al, 1983;Orell & Dowling 1983;Hilborne et al, 1985).…”

Section: Resultsmentioning

confidence: 99%

“…The increasing availability of monoclonal antibodies to tumour associated antigens (TAA) has led to their use as an adjunct in cytodiagnosis of solid tumours (Ghosh et al, 1983;Johnston et al, 1985;Martin et al, 1988). This has already resulted in a significant improvement of the diagnosis of serous effusions occurring in patients with unknown primary cancer (Mottolese et al, 1988).…”

mentioning

confidence: 99%

Use of MoAb D612 in combination with a panel of MoAb for the immunocytochemical identification of metastases from colon-rectum carcinoma

Mottolese¹,

Venturo

Digiesi

et al. 1990

Br J Cancer

View full text Add to dashboard Cite

Summary During the course of colon-rectum tumours a number of clinical events may occur in which conventional cytopathology can provide only a partial contribution to the definition of a differential diagnosis, i.e. effusions, distant recurrences and second neoplasias. In the present study we have evaluated whether monoclonal antibody (MoAb) D612, recognising a colon-rectum associated antigen, can be used in this context. To this end, MoAb D612 was employed in combination with a panel of MoAb of well defined tumour specificity in immunocytochemical tests. The immunocytochemical findings obtained were compared with the histological and clinical diagnosis. Of 62 effusions and 40 fine needle aspirates studied, MoAb D612 reactivity correlated with the correct diagnosis in 92.8% of the instances. These results indicate that this reagent may help to improve the current cytopathological diagnosis of colon-rectum tumours by identifying the colonic origin of metastases in patients with unknown primary tumour, differentiating ovarian carcinoma from colon metastases to the ovaries and establishing the presence of a second neoplasia in patients with a previous history other than colon carcinoma.

show abstract

“…This is a powerful technique which has already been of proven value in general histological and cytological practice (Gatter et al 1982, Ghosh et al 1983.…”

Section: Resultsmentioning

confidence: 99%